

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Currently Amended): A method for downregulating HIV-1 fusion cofactor expression in a T cell, comprising contacting the T cell with a solid phase surface comprising an anti-CD28 antibody and an anti-CD3 antibody *in vitro*, thereby downregulating HIV-1 fusion cofactor expression in the T cell, wherein the T cell is more resistant to infection by an M-tropic HIV isolate than a T cell not contacted with the solid phase surface.

Claims 2-54 (Cancelled)

Claim 55. (Currently Amended): A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell with a solid phase surface comprising an anti-CD28 antibody and an anti-CD3 antibody *in vitro*, thereby downregulating CCR5 expression in the T cell, wherein the T cell is more resistant to infection by an M-tropic HIV isolate than a T cell not contacted with the solid phase surface.

Claims 56-59 (Cancelled)

Claim 60. (Currently Amended): A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell with a solid phase surface comprising an anti-CD28 antibody and an anti-CD3 antibody *in vivo*, thereby downregulating CCR5 expression in a T cell, wherein the T cell is more resistant to infection by an M-tropic HIV isolate than a T cell not contacted with the solid phase surface.

Claims 61-74 (Cancelled)

Claim 75. (Currently Amended): A method for downregulating HIV-1 fusion cofactor expression in a T cell, comprising contacting the T cell with a solid phase surface comprising an anti-CD28 antibody and an anti-CD3 antibody *in vivo*, thereby downregulating HIV-1 fusion cofactor expression in the T cell, wherein the T cell is more resistant to infection by an M-tropic HIV isolate than a T cell not contacted with the solid phase surface.

Claims 76-86 (Cancelled)

Claim 87. (Previously Presented) The method of any one of claims 1, 55, 60, or 75, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

Claim 88. (Previously Presented) The method of any one of claims 1, 55, 60, or 75, wherein the anti-CD28 antibody is an anti-human CD28 monoclonal antibody.

Claim 89. (Previously Presented) The method of any one of claims 1, 55, 60, or 75, wherein said solid phase surface is a bead.

Claim 90. (Previously Presented) The method of claim 89, wherein the bead is a magnetic immunobead.

Claim 91. (Previously Presented) The method of any one of claims 1 or 55, wherein said solid phase surface is a tissue culture dish.

Claim 92. (Previously Presented) The method of any one of claims 1, 55, 60, or 75, wherein the anti-CD3 antibody and the anti-CD28 antibody are immobilized on the solid phase via a covalent modification.

Claim 93. (Previously Presented) The method of any one of claims 1, 55, 60, or 75, wherein the anti-CD3 antibody and the anti-CD28 antibody are immobilized on the solid phase surface via an avidin-biotin complex.

Claim 94. (Previously Presented) The method of any one of claims 1, 55, 60, or 75, wherein the anti-CD3 antibody and the anti-CD28 antibody are directly immobilized on the solid phase surface.